A significant breakthrough in contemporary cardiology was the finding that sodium–glucose-cotransporter-2 (SGLT2) inhibitors are associated with a lower risk of heart failure (HF) hospitalisation in patients with or at high risk of CV disease.2 A selective inhibitor of SGLT2, Empagliflozin, reduces rates of hyperglycaemia in T2D patients by decreasing renal glucose reabsorption, thereby increasing urinary glucose excretion.3 In addition, SGLT2 inhibition causes a modest rapid reduction in weight, haemoconcentration and reduced blood pressure, consistent with a diuretic effect (2,3). Here, SLC5A2 is linked to heart failure.